UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

NOTICE OF EFFECTIVENESS

Effective Date:April 16,
Verastem (NASDAQ:VSTM)
Historical Stock Chart
From Apr 2024 to May 2024 Click Here for more Verastem Charts.
Verastem (NASDAQ:VSTM)
Historical Stock Chart
From May 2023 to May 2024 Click Here for more Verastem Charts.

Verastem, Inc. News

Verastem Oncology Announces Appointment of John Hayslip, M.D., to Chief Medical Officer
Friday 19 April 2024 (2 weeks ago) • Business Wire
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Thursday 4 April 2024 (1 month ago) • Business Wire
Global Patient Survey Results Reveal Significant Negative Impact on Social, Emotional and Mental Well-Being for People Living with Low-Grade Serous Ovarian Cancer
Monday 18 March 2024 (2 months ago) • Business Wire
Verastem Oncology Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Business Updates
Friday 15 March 2024 (2 months ago) • Business Wire
Form SC TO-I/A - Tender offer statement by Issuer: [Amend]
Tuesday 12 March 2024 (2 months ago) • Edgar (US Regulatory)
Verastem Oncology Announces Multiple Oral Presentations at SGO 2024 Annual Meeting on Women’s Cancer that Highlight Advances in Low-Grade Serous Ovarian Cancer Research and Reinforce Commitment to Addressing Urgent Unmet Needs
Monday 11 March 2024 (2 months ago) • Business Wire
Verastem Oncology Receives Orphan Drug Designation from FDA for Avutometinib Alone or in Combination With Defactinib in Recurrent Low-Grade Serous Ovarian Cancer
Wednesday 6 March 2024 (2 months ago) • Business Wire
Verastem Oncology Announces Preclinical Presentations for New Oral G12D Inhibitor and for Avutometinib and Defactinib Combination as a Backbone of Therapy for RAS/MAPK Driven Cancers at AACR Annual Meeting 2024
Wednesday 6 March 2024 (2 months ago) • Business Wire
Form SC TO-I - Tender offer statement by Issuer
Friday 9 February 2024 (3 months ago) • Edgar (US Regulatory)
Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
Saturday 3 February 2024 (3 months ago) • Edgar (US Regulatory)
Form 8-K - Current report
Tuesday 30 January 2024 (3 months ago) • Edgar (US Regulatory)
Verastem Oncology Outlines Key 2024 Strategic Priorities and Upcoming Catalysts for Advancing Avutometinib and Defactinib and Broader Pipeline in RAS Pathway-Driven Cancers
Monday 29 January 2024 (3 months ago) • Business Wire

More Verastem, Inc. News Articles